硝苯地平与拉贝洛尔治疗妊娠期高血压的策略:Giant PANDA 随机对照试验研究方案
Giant PANDA 是一项实用性、开放标签、多中心随机对照试验,计划纳入 2300 例妊娠期高血压女性,比较以硝苯地平(钙通道阻滞剂)与拉贝洛尔(α/β 混合阻滞剂)起始治疗的策略。主要目标是评估硝苯地平相比拉贝洛尔能否在不增加胎儿或新生儿死亡或新生儿病房入住的情况下减少重度母体高血压。试验结果旨在为指南和共享决策工具提供确定性证据。
要点
- Giant PANDA 计划纳入 2300 例妊娠期高血压女性,比较硝苯地平与拉贝洛尔起始治疗策略。
- 主要目标为评估硝苯地平是否减少重度母体高血压且不增加胎儿或新生儿死亡或新生儿病房入住。
- 将按高血压类型、糖尿病、单胎、自报种族和随机化时孕周进行亚组分析,并进行成本-后果分析。
核心结论
- 该试验旨在解决哪种降压治疗与最佳母婴结局相关的不确定性,试验结果拟为指南和共享决策工具提供确定性证据,从而影响临床实践。
研究设计与样本
- Giant PANDA 研究是一项实用性、开放标签、多中心、随机对照试验,比较以硝苯地平(钙通道阻滞剂)与拉贝洛尔(α/β 混合阻滞剂)起始治疗的策略,计划纳入 2300 例妊娠期高血压女性。
- 亚组分析将按高血压类型(慢性、妊娠期、子痫前期)、糖尿病(有、无)、单胎(是、否)、自报种族(黑人、所有其他)和随机化时孕周分类(11+0 至 19+6 周、20+0 至 27+6 周、28+0 至 34+6 周)进行。
- 将采用 NHS 视角进行成本-效果分析,包括至产后出院时的成本-后果分析,以及根据成本-后果分析结果进行的终生 horizon 外推分析。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Approximately one in ten women have high blood pressure during pregnancy. Hypertension is associated with adverse maternal and perinatal outcomes, and as treatment improves maternal outcomes, antihypertensive treatment is recommended. Previous trials have been unable to provide a definitive answer on which antihypertensive treatment is associated with optimal maternal and neonatal outcomes and the need for robust evidence evaluating maternal and infant benefits and risks remains an important, unanswered question for research and clinical communities. METHODS: The Giant PANDA study is a pragmatic, open-label, multicentre, randomised controlled trial of a treatment initiation strategy with nifedipine (calcium channel blocker), versus labetalol (mixed alpha/beta blocker) in 2300 women with pregnancy hypertension. The primary objective is to evaluate if treatment with nifedipine compared to labetalol in women with pregnancy hypertension reduces severe maternal hypertension without increasing fetal or neonatal death or neonatal unit admission. Subgroup analyses will be undertaken by hypertension type (chronic, gestational, pre-eclampsia), diabetes (yes, no), singleton (yes, no), self-reported ethnicity (Black, all other), and gestational age at randomisation categories (11 + 0 to 19 + 6, 20 + 0 to 27 + 6, 28 + 0 to 34 + 6 weeks). A cost-effectiveness analysis using an NHS perspective will be undertaken using a cost-consequence analysis up to postnatal hospital discharge and an extrapolation exercise with a lifetime horizon conditional on the results of the cost-consequence analysis. DISCUSSION: This trial aims to address the uncertainty of which antihypertensive treatment is associated with optimal maternal and neonatal outcomes. The trial results are intended to provide definitive evidence to inform guidelines and linked, shared decision-making tools, thus influencing clinical practice. TRIAL REGISTRATION: EudraCT number: 2020-003410-12, ISRCTN: 12,792,616 registered on 18 November 2020.
引用
- Ashworth D, Battersby C, Bick D, et al. A treatment strategy with nifedipine versus labetalol for women with pregnancy hypertension: study protocol for a randomised controlled trial (Giant PANDA). Trials. 2023. PMID: 37700365. doi:10.1186/s13063-023-07582-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。